申请人:Sterling Drug Inc.
公开号:US04412077A1
公开(公告)日:1983-10-25
4-R.sub.2 -5-(Lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones (I), useful as cardiotonics, where R.sub.2 is hydrogen or methyl, are prepared by reacting 2-(lower-alkanoyl)-1-(lower-alkyl)ethenamine (II) with lower-alkyl 2-propynoate or 2-butynoate respectively or by hydrolyzing 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinonitrile (III, Q is CN) or corresponding 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinamide to produce the corresponding 5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinic acid and decarboxylating said substituted nictotinic acid to produce I. Also disclosed and claimed are cardiotonic uses of 3-Q-4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones where Q is hydrogen or cyano and R.sub.2 is hydrogen or methyl (III). Also shown and claimed is methyl 4-acetyl-5-amino-2,4-hexadienoate or acid-addition salt thereof, useful as intermediate or cardiotonic.
4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-2(1H)-吡啶酮(I),作为心力衰竭药物,其中R.sub.2为氢或甲基,通过将2-(较低烷酰基)-1-(较低烷基)乙烯胺(II)与较低烷基2-丙炔酸酯或2-丁炔酸酯分别反应或通过水解4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-1,2-二氢-2-氧基烟酰亚胺(III,其中Q为CN)或相应的4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-1,2-二氢-2-氧基烟酰胺来制备相应的5-(较低烷酰基)-6-(较低烷基)-1,2-二氢-2-氧基烟酸,并脱羧所述取代烟酸产生I。还披露和声称3-Q-4-R.sub.2 -5-(较低烷酰基)-6-(较低烷基)-2(1H)-吡啶酮的心力衰竭用途,其中Q为氢或氰基,R.sub.2为氢或甲基(III)。还展示和声称4-乙酰基-5-氨基-2,4-己二烯酸甲酯或其酸盐,作为中间体或心力衰竭药物。